|Bid||0.00 x 800|
|Ask||0.00 x 2200|
|Day's Range||5.94 - 6.10|
|52 Week Range||4.20 - 29.49|
|Beta (3Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the […]
In 2000 Gregory Went was appointed CEO of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). This analysis aims first to...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
Adamas (ADMS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Emeryville, California-based company said it had a loss of $1.08. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of vo...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AptarGroup (ATR) fourth-quarter results will benefit from successful product roll outs and focus on improving operations despite input cost inflation and customer plant shutdowns.